IBDEI31Q ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,48639,1,4,0)
 ;;=4^I69.931
 ;;^UTILITY(U,$J,358.3,48639,2)
 ;;=^5007558
 ;;^UTILITY(U,$J,358.3,48640,0)
 ;;=I69.933^^185^2424^37
 ;;^UTILITY(U,$J,358.3,48640,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,48640,1,3,0)
 ;;=3^Cerebrovascular Disease,Monoplegia,Rt Upper Nondominant Side
 ;;^UTILITY(U,$J,358.3,48640,1,4,0)
 ;;=4^I69.933
 ;;^UTILITY(U,$J,358.3,48640,2)
 ;;=^5007559
 ;;^UTILITY(U,$J,358.3,48641,0)
 ;;=I69.998^^185^2424^44
 ;;^UTILITY(U,$J,358.3,48641,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,48641,1,3,0)
 ;;=3^Cerebrovascular Disease,Sequelae,Unspec
 ;;^UTILITY(U,$J,358.3,48641,1,4,0)
 ;;=4^I69.998
 ;;^UTILITY(U,$J,358.3,48641,2)
 ;;=^5007572
 ;;^UTILITY(U,$J,358.3,48642,0)
 ;;=I69.928^^185^2424^45
 ;;^UTILITY(U,$J,358.3,48642,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,48642,1,3,0)
 ;;=3^Cerebrovascular Disease,Speech/Language Deficits,Unspec
 ;;^UTILITY(U,$J,358.3,48642,1,4,0)
 ;;=4^I69.928
 ;;^UTILITY(U,$J,358.3,48642,2)
 ;;=^5007557
 ;;^UTILITY(U,$J,358.3,48643,0)
 ;;=I69.965^^185^2424^39
 ;;^UTILITY(U,$J,358.3,48643,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,48643,1,3,0)
 ;;=3^Cerebrovascular Disease,Paralytic Syndrome,Bilateral,Unspec
 ;;^UTILITY(U,$J,358.3,48643,1,4,0)
 ;;=4^I69.965
 ;;^UTILITY(U,$J,358.3,48643,2)
 ;;=^5007566
 ;;^UTILITY(U,$J,358.3,48644,0)
 ;;=I69.962^^185^2424^40
 ;;^UTILITY(U,$J,358.3,48644,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,48644,1,3,0)
 ;;=3^Cerebrovascular Disease,Paralytic Syndrome,Lt Dominant Side
 ;;^UTILITY(U,$J,358.3,48644,1,4,0)
 ;;=4^I69.962
 ;;^UTILITY(U,$J,358.3,48644,2)
 ;;=^5133588
 ;;^UTILITY(U,$J,358.3,48645,0)
 ;;=I69.964^^185^2424^41
 ;;^UTILITY(U,$J,358.3,48645,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,48645,1,3,0)
 ;;=3^Cerebrovascular Disease,Paralytic Syndrome,Lt Nondominant Side
 ;;^UTILITY(U,$J,358.3,48645,1,4,0)
 ;;=4^I69.964
 ;;^UTILITY(U,$J,358.3,48645,2)
 ;;=^5133589
 ;;^UTILITY(U,$J,358.3,48646,0)
 ;;=I69.961^^185^2424^42
 ;;^UTILITY(U,$J,358.3,48646,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,48646,1,3,0)
 ;;=3^Cerebrovascular Disease,Paralytic Syndrome,Rt Dominant Side
 ;;^UTILITY(U,$J,358.3,48646,1,4,0)
 ;;=4^I69.961
 ;;^UTILITY(U,$J,358.3,48646,2)
 ;;=^5007564
 ;;^UTILITY(U,$J,358.3,48647,0)
 ;;=I69.963^^185^2424^43
 ;;^UTILITY(U,$J,358.3,48647,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,48647,1,3,0)
 ;;=3^Cerebrovascular Disease,Paralytic Syndrome,Rt Nondominant Side
 ;;^UTILITY(U,$J,358.3,48647,1,4,0)
 ;;=4^I69.963
 ;;^UTILITY(U,$J,358.3,48647,2)
 ;;=^5007565
 ;;^UTILITY(U,$J,358.3,48648,0)
 ;;=G90.50^^185^2424^52
 ;;^UTILITY(U,$J,358.3,48648,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,48648,1,3,0)
 ;;=3^Complex Regional Pain Syndrome I,Unspec
 ;;^UTILITY(U,$J,358.3,48648,1,4,0)
 ;;=4^G90.50
 ;;^UTILITY(U,$J,358.3,48648,2)
 ;;=^5004163
 ;;^UTILITY(U,$J,358.3,48649,0)
 ;;=R56.9^^185^2424^53
 ;;^UTILITY(U,$J,358.3,48649,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,48649,1,3,0)
 ;;=3^Convulsions,Unspec
 ;;^UTILITY(U,$J,358.3,48649,1,4,0)
 ;;=4^R56.9
 ;;^UTILITY(U,$J,358.3,48649,2)
 ;;=^5019524
 ;;^UTILITY(U,$J,358.3,48650,0)
 ;;=G37.9^^185^2424^54
 ;;^UTILITY(U,$J,358.3,48650,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,48650,1,3,0)
 ;;=3^Demyelinating Disease of Central Nervous System,Unspec
 ;;^UTILITY(U,$J,358.3,48650,1,4,0)
 ;;=4^G37.9
 ;;^UTILITY(U,$J,358.3,48650,2)
 ;;=^5003828
 ;;^UTILITY(U,$J,358.3,48651,0)
 ;;=G36.9^^185^2424^55
